HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The recent major shift toward oral direct acting hepatitis C virus (HCV) treatments has the potential to revolutionize the global response to HCV. People who inject drugs (PWID) are a large key affected population who stand to benefit from these new medications. RECENT FINDINGS: There is a large number of new drug classes and targets with activity against HCV. Although effective for HCV treatment in monoinfection and coinfection with HIV, most direct-acting antivirals (DAAs) remain within the research pipeline, with only two having achieved regulatory approval to date. Clinical trial data are not available regarding HCV treatment for PWID with DAAs. This article reviews clinical data on HCV treatment for a number of promising compounds in HCV monoinfection and coinfection with HIV and discusses the barriers facing PWID in scale-up and roll-out of DAAs in the coming years. SUMMARY: DAAs have the potential to revolutionize HCV treatment. There will be significant access barriers for people who inject drugs to these new medications.
Original languageEnglish
Pages (from-to)339 - 344
Number of pages6
JournalCurrent Opinion in HIV and AIDS
Volume7
Issue number4
DOIs
Publication statusPublished - 2012

Cite this